The Association of Baseline Serum Tumour Markers with Outcome
of Patients with Metastatic Colorectal Cancer Treated with
Anti-EGFR Monoclonal Antibodies in the First Line

J 2018

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line

FIALA, Ondrej, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER et. al.

Basic information

Original name

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line

Authors

FIALA, Ondrej (203 Czech Republic, guarantor), Petr HOSEK (203 Czech Republic), Ondrej SOREJS (203 Czech Republic), Vaclav LISKA (203 Czech Republic), Tomas BUCHLER (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Radek KUCERA (203 Czech Republic), Ondrej TOPOLCAN (203 Czech Republic), Monika SEDIVCOVA (203 Czech Republic) and Jindrich FINEK (203 Czech Republic)

Edition

JOURNAL OF CANCER, LAKE HAVEN, IVYSPRING INT PUBL, 2018, 1837-9664

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Australia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.182

RIV identification code

RIV/00216224:14110/18:00106289

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.7150/jca.26217

UT WoS

000447850000020

Keywords in English

colorectal cancer; cetuximab; panitumumab; chemotherapy; tumor markers; serum carcinoembryonic antigen; carbohydrate antigen 19-9; thymidine kinase; tissue polypeptide specific antigen

Abstract

V originále

The measurement of serum tumour markers is a simple and non-invasive method for assessing the response to systemic therapies in metastatic colorectal cancer (mCRC) and estimation of prognosis. The aim of our retrospective study was to evaluate the association of baseline serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) with outcome of patients with mCRC treated with combination of chemotherapy and monoclonal antibodies against epidermal growth factor receptor (anti-EGFR mAbs) in the first line. In our study, the cohort included 102 patients treated with therapy based on anti-EGFR mAbs between years 2011 and 2017 at Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Czech Republic. Serum samples were collected within one month before the initiation of treatment. In multivariate Cox analysis that included serum tumour markers and clinical baseline parameters show that high baseline serum CA 19-9 was significantly associated with worse progression-free survival (HR=1.871, p=0.0330) and also overall survival (HR=3.903, p=0.0006). We have not demonstrated association of baseline levels of CEA, TK and TPS with patients' outcome. CA 19-9 is commonly used serum tumour marker which is simple and readily available and its candidate prognostic importance in the setting of anti-EGFR therapy deserves to be studied in prospective trials.

Citovat

FIALA, Ondrej, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Monika SEDIVCOVA and Jindrich FINEK. The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. JOURNAL OF CANCER. LAKE HAVEN: IVYSPRING INT PUBL, 2018, vol. 9, No 22, p. 4255-4262. ISSN 1837-9664. Available from: https://dx.doi.org/10.7150/jca.26217.

@article{1499616,
   author = {Fiala, Ondrej and Hosek, Petr and Sorejs, Ondrej and Liska, Vaclav and Buchler, Tomas and Poprach, Alexandr and Kucera, Radek and Topolcan, Ondrej and Sedivcova, Monika and Finek, Jindrich},
   article_location = {LAKE HAVEN},
   article_number = {22},
   doi = {http://dx.doi.org/10.7150/jca.26217},
   keywords = {colorectal cancer; cetuximab; panitumumab; chemotherapy; tumor markers; serum carcinoembryonic antigen; carbohydrate antigen 19-9; thymidine kinase; tissue polypeptide specific antigen},
   language = {eng},
   issn = {1837-9664},
   journal = {JOURNAL OF CANCER},
   title = {The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line},
   volume = {9},
   year = {2018}
}

TY  - JOUR
ID  - 1499616
AU  - Fiala, Ondrej - Hosek, Petr - Sorejs, Ondrej - Liska, Vaclav - Buchler, Tomas - Poprach, Alexandr - Kucera, Radek - Topolcan, Ondrej - Sedivcova, Monika - Finek, Jindrich
PY  - 2018
TI  - The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line
JF  - JOURNAL OF CANCER
VL  - 9
IS  - 22
SP  - 4255-4262
EP  - 4255-4262
PB  - IVYSPRING INT PUBL
SN  - 18379664
KW  - colorectal cancer
KW  - cetuximab
KW  - panitumumab
KW  - chemotherapy
KW  - tumor markers
KW  - serum carcinoembryonic antigen
KW  - carbohydrate antigen 19-9
KW  - thymidine kinase
KW  - tissue polypeptide specific antigen
N2  - The measurement of serum tumour markers is a simple and non-invasive method for assessing the response to systemic therapies in metastatic colorectal cancer (mCRC) and estimation of prognosis. The aim of our retrospective study was to evaluate the association of baseline serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) with outcome of patients with mCRC treated with combination of chemotherapy and monoclonal antibodies against epidermal growth factor receptor (anti-EGFR mAbs) in the first line. In our study, the cohort included 102 patients treated with therapy based on anti-EGFR mAbs between years 2011 and 2017 at Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Czech Republic. Serum samples were collected within one month before the initiation of treatment. In multivariate Cox analysis that included serum tumour markers and clinical baseline parameters show that high baseline serum CA 19-9 was significantly associated with worse progression-free survival (HR=1.871, p=0.0330) and also overall survival (HR=3.903, p=0.0006). We have not demonstrated association of baseline levels of CEA, TK and TPS with patients' outcome. CA 19-9 is commonly used serum tumour marker which is simple and readily available and its candidate prognostic importance in the setting of anti-EGFR therapy deserves to be studied in prospective trials.
ER  -

FIALA, Ondrej, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Monika SEDIVCOVA and Jindrich FINEK. The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. \textit{JOURNAL OF CANCER}. LAKE HAVEN: IVYSPRING INT PUBL, 2018, vol.~9, No~22, p.~4255-4262. ISSN~1837-9664. Available from: https://dx.doi.org/10.7150/jca.26217.

Detailed Information on Publication Record